Reading Time: 7 minutes Researchers from the University of Aberdeen and the University of Edinburgh have developed a new tool that could help to detect signs of MND in cells before symptoms of the disease start. This work was recently published and was previously presented at the 34th International Symposium in Basel by Dr Jenna Gregory. The new tool…
Reading Time: 4 minutes Hello everyone. My name is Genevieve (Gen) and I have joined the Association as Philanthropy Information Officer. One of my roles is to communicate the progress made by our MND researchers, in layman’s terms, to the major donors and Trusts who generously fund much of our research. I will also be sharing research updates more…
Reading Time: 6 minutes Over the past couple of years, the pace of MND research has continued to increase. In the last year alone, we saw an increase in the number of MND clinical trials recruiting worldwide. During 2023 we heard some promising results from early trials and Tofersen (Qalsody), a treatment for SOD1 MND, was approved for use…
Reading Time: 6 minutes MND is a very complex disease, and in the UK there is still only one approved treatment so the need for more effective treatments remains at the forefront of MND research. There have been over 140 clinical trials for MND over the last several decades and the majority of these have, unfortunately, not led to…
Reading Time: 4 minutes A new clinical trial, investigating Dazucorilant, for the treatment of MND is now open for recruitment in the UK. With this trial, there are now 6 clinical trials recruiting in the UK, further highlighting the current momentum in finding potential effective treatments for MND. People living with MND often show signs of over-active adrenal glands,…
Reading Time: 7 minutes On 25th April 2023 Tofersen (now known as Qalsody in the US), a treatment for SOD1 MND was approved by the Food and Drug Administration (FDA) in the United States. The FDA approval in the US is a welcome step forward in the fight against MND and further highlights the commitment and dedication of the…
Reading Time: 6 minutes Over the last year ALS/MND clinical trials have taken centre stage, with more trials than ever opening for recruitment in the UK, the news of promising results from some trials and the approval of drugs by some regulatory authorities. With the year coming to an end, we thought we would roundup some recent clinical trial updates that were presented at the 33rd International Symposium on ALS/MND.
Reading Time: 5 minutes The top-line results of the Modifying Immune Response and OutComes in ALS (MIROCALS) clinical trial were announced on 6 December 2022 at the 33rd International Symposium on ALS/MND. As part of the clinical trials session, the scientific leads Dr Gilbert Bensimon and Professor Nigel Leigh discussed the study design and outcomes (C03). MIROCALS was an 18-month,…
Reading Time: 6 minutes A recent paper (October 2022), published in the journal Journal of Pathology: Clinical Research suggests that evidence of MND can be seen inside people years before they develop physical symptoms. The paper titled ‘pTDP-43 aggregates accumulate in non-central nervous system tissues prior to symptom onset in amyotrophic lateral sclerosis: a case series linking archival surgical biopsies…
Reading Time: 6 minutes On Tuesday 4 October 2022, a new paper was published which investigated the risk of developing a neurodegenerative disease, such as MND, among former Scottish international rugby players. The paper concluded that former Scottish international rugby union players had an increased risk of developing MND compared to the general population. We sat down with Dr…
